Testimony on Rilonacept (ARCALYST) to the FDA's Arthritis Advisory Committee
May 8, 2012
Public Citizen strongly opposes the FDA’s approval of rilonacept for the prevention of gout flares because the drug provides no unique advantages over current treatment options and has known risks of serious infections and signals related to malignancies and adverse cardiovascular events.
View as PDF
View the press release